C. Ruff, R. Giugliano, and E. Braunwald, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, The Lancet, vol.383, issue.9921, pp.955-962, 2014.
DOI : 10.1016/S0140-6736(13)62343-0

URL : https://hal.archives-ouvertes.fr/hal-00935589

A. Cohen, M. Hamilton, and S. Mitchell, Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis, PLOS ONE, vol.8, issue.11, p.144856, 2015.
DOI : 10.1371/journal.pone.0144856.s007

A. Delluc, L. Ven, F. Mottier, and D. , ??pid??miologie et facteurs de risque de la maladie veineuse thromboembolique, Revue des Maladies Respiratoires, vol.29, issue.2, pp.254-266, 2012.
DOI : 10.1016/j.rmr.2011.12.001

A. Godier, A. Martin, and I. Leblanc, Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations, Thrombosis Research, vol.136, issue.4, pp.763-768, 2015.
DOI : 10.1016/j.thromres.2015.08.006

T. Steiner, M. Bohm, and M. Dichgans, Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban, Clinical Research in Cardiology, vol.105, issue.3, pp.399-412, 2013.
DOI : 10.1038/ajg.2009.712

G. Pernod, P. Albaladejo, and A. Godier, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) ??? March 2013, Archives of Cardiovascular Diseases, vol.106, issue.6-7, pp.382-393, 2013.
DOI : 10.1016/j.acvd.2013.04.009

C. Miller, S. Grandi, and A. Shimony, Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation, The American Journal of Cardiology, vol.110, issue.3, pp.453-460, 2012.
DOI : 10.1016/j.amjcard.2012.03.049

C. Chai-adisaksopha, M. Crowther, and T. Isayama, The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis, Blood, vol.124, issue.15, pp.2450-2458, 2014.
DOI : 10.1182/blood-2014-07-590323

E. Investigators, R. Bauersachs, and S. Berkowitz, Oral rivaroxaban for symptomatic venous thromboembolism, New Engl J Med, vol.363, pp.2499-2510, 2010.

G. Agnelli, H. Buller, and A. Cohen, Oral Apixaban for the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.369, issue.9, pp.799-808, 2013.
DOI : 10.1056/NEJMoa1302507

URL : https://hal.archives-ouvertes.fr/hal-00932477

T. Larsen, L. Rasmussen, and F. Skjoth, Efficacy and Safety of Dabigatran Etexilate and Warfarin in ???Real-World??? Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.61, issue.22, pp.2264-2273, 2013.
DOI : 10.1016/j.jacc.2013.03.020

J. Beyer-westendorf, K. Forster, and S. Pannach, Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry, Blood, vol.124, issue.6, pp.955-962, 2014.
DOI : 10.1182/blood-2014-03-563577

A. Benard-laribiere, G. Miremont-salame, and M. Perault-pochat, Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study, Fundamental & Clinical Pharmacology, vol.88, issue.1, pp.106-111, 2015.
DOI : 10.1016/j.mayocp.2013.03.006

F. Cotte, G. Chaize, and I. Kachaner, Incidence and Cost of Stroke and Hemorrhage in Patients Diagnosed with Atrial Fibrillation in France, Journal of Stroke and Cerebrovascular Diseases, vol.23, issue.2, pp.73-83, 2014.
DOI : 10.1016/j.jstrokecerebrovasdis.2013.08.022